Exhibit 10.13


    
      

    


    Gencarelli
      Group

    209
      Pennsylvania Avenue, SE

    Washington,
      D.C. 20003

    (202)543-6972

    


    December
      29, 2006

    


    Eugene
      Seymour, MD

    Chief
      Executive Officer

    Nanoviricides,
      Inc.

    135
      Wood
      Street, Suite 205

    West
      Haven, Connecticut 06516

    


    Re:
      Nanoviricides, Inc. Collaboration with U.S. Military and Civilian Research
      Agencies and International Health Agencies, 2006-2007

    


    Dear
      Dr.
      Seymour:

    


    I
      am
      writing to establish a record of work done in recent months to put in
place
      formal collaborative arrangements between Nanoviricides, Inc. and U.S. Federal
      research agencies.

    


    U.S.
      Military—Walter Reed Army Institute for Research (WRAIR)

    


    In
      June
      of 2006 Nanoviricides, Inc. began discussions with Colonel Julia Lynch, Chief,
      Infectious Diseases, WRAIR, about possible common interests and goals
      in
      the area of anti-viral treatment research. This meeting led to technical
      discussions in September wherein Colonel Joseph Robert Putnak, Ph.D., Director,
      Division of Virus Diseases, WRAIR, initiated dialogue with Nanoviricides, Inc.
      about a Cooperative Research and Development Agreement (CRADA) designed to
      test
      the effectiveness of the Nanoviricides, Inc. anti-viral approach against three
      diseases of interest at WRAIR, namely Dengue Fever, West Nile Virus and Japanese
      Equine Encephalitis (JEE). 

    


    As
      of
      December 22, 2006, Nanoviricides, Inc. officials have submitted required
      information for formalization of the CRADA and await sign-off by WRAIR officials
      so that work can begin within 45-60 days. This work will initially test a
      combination of the Nanoviricides, Inc. polymer and targeting antibody fragments
      derived from the specified diseases against the three diseases themselves in
      an
      in vitro setting. When these in vitro tests show adequate effectiveness, it
      is
      WRAIR’s intention to continue testing with this combination in primates where
      Dengue fever will be the primary focus. Nanoviricides, Inc. can reasonably
      expects both of these experimental tracks to move forward during the 2007
      calendar year.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    


    Page
      2-Nanoviricides, Inc. Collaboration with U.S. Military and Civilian Research
      Agencies, 2006-2007

    


    United
      States National Institute for Allergies and Infectious Disease
      (US-NIAID)

    


    Nanoviricides,
      Inc. began discussions in September of this year with Dr. Roland Levandowski
      Chief, Influenza, SARS, and Other Viral Respiratory Diseases Section Division
      of Microbiology
      and Infectious Diseases NIAID/NIH/DHH, and program manager Heather Greenstone
      about participating in NIAID’s Small business testing and evaluation
      program which provides no-cost testing of novel immunotherapeutic treatment
      and
      vaccines against diseases considered priorities for the Institute.
      Nanoviricides, Inc. and NIAID are now in the process of finalizing paperwork
      for
      bioassay (in vitro) testing to be done against HIV (AIDS), Influenzas, H5N1,
      SARS, and Herpes over the next few months. Assuming adequate effectiveness
      is
      shown in the in vitro testing, the goal will be to move on to animal studies
      on
      the same diseases. Actual experimentation will be done by NIAID contractor
      Utah
      State with all costs (other than production of Nanoviricides, Inc. materials)
      borne by NIAID. NIAID has indicated that if there are no unforeseen delays,
      both
      bioassay and animal studies could begin before the end of calendar year
      2007.

    


    Also
      in
      2006, Nanoviricides, Inc. has spent time exploring possible collaboration
      opportunities with foreign research institutes under the auspices of the Pan
      American Health Organization and the World Health Organization. The company
      has
      met on numerous occasions with Dr. John Ehrenberg of PAHO, well known for his
      efforts to bring novel pharmaceutical solutions to populations in underdeveloped
      countries where “orphan” or “neglected” disease take an inordinate toll on
      indigenous peoples. One of his most important contributions has been arrangement
      of collaborations with the pharmaceutical industry which have significantly
      reduced river blindness sickness in Africa. With Dr. Ehrenberg’s encouragement,
      Nanoviricides, Inc. has met with Dr. Robert Ridley, Executive Director, Tropical
      Disease Research Institute of the WHO, in Washington, DC and later in Geneva,
      Switzerland to identify target diseases and research institutes in South and
      Central America which that may be potential collaborators. This work is expected
      to produce commercial and humanitarian opportunities relating to diseases common
      to this region of the world.

    


    I
      hope
      this summary adequately explains the state of play between Nanoviricides, Inc.
      and two key government collaborators. Gencarelli Group stands ready to answer
      detailed questions on these projects.

    


    
      	 	 	
              Dave
                Gencarelli, Gencarelli Group 

            
	 	 	
              202-256-6191